Patents Assigned to Crystalgenomics, Inc.
-
Patent number: 11655207Abstract: The present invention relates to a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of a derivative thereof and a method for preparing same, and can improve moisture stability while maintaining the characteristics, such as the efficacy and effective dose, of a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of a derivative thereof. In addition, the present invention can simplify the production and manufacturing process of a formulation by improving hygroscopicity.Type: GrantFiled: April 18, 2018Date of Patent: May 23, 2023Assignee: CRYSTALGENOMICS, INC.Inventors: Jae Pyoung Cho, Yong Ho Jung, Joong Myung Cho
-
Patent number: 11602517Abstract: The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.Type: GrantFiled: March 20, 2019Date of Patent: March 14, 2023Assignee: CrystalGenomics, Inc.Inventors: Jae Pyoung Cho, Joong Myung Cho
-
Patent number: 11230539Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by absormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.Type: GrantFiled: February 14, 2020Date of Patent: January 25, 2022Assignee: CrystalGenomics, Inc.Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
-
Patent number: 10604508Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.Type: GrantFiled: August 30, 2017Date of Patent: March 31, 2020Assignee: CrystalGenomics, Inc.Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
-
Patent number: 10413520Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.Type: GrantFiled: June 22, 2017Date of Patent: September 17, 2019Assignee: CRYSTALGENOMICS, INC.Inventors: Byung-Ha Kim, Sik II Ahn, Jae-Yeon Park, Tae Ryong Kim, Joong Myung Cho, Seonggu Ro
-
Publication number: 20180344702Abstract: The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.Type: ApplicationFiled: February 21, 2018Publication date: December 6, 2018Applicants: Aptose Biosciences Inc., CrystalGenomics, Inc.Inventors: William G. RICE, Joong Myung CHO, Yongrae HONG
-
Patent number: 9758508Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.Type: GrantFiled: December 26, 2013Date of Patent: September 12, 2017Assignee: CrystalGenomics, Inc.Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
-
Publication number: 20120135989Abstract: The present invention provides a (di)azaindole derivative represented by the formula (I). A compound of the present invention inhibits a Cdc7 protein kinase activity and suppresses cell proliferation.Type: ApplicationFiled: June 29, 2011Publication date: May 31, 2012Applicants: CRYSTALGENOMICS, INC., SBI BIOTECH CO., LTD.Inventors: Yoko Funakoshi, Chika Tanaka, Choul Hong Park, Seong Gu Ro
-
Patent number: 8119812Abstract: An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.Type: GrantFiled: April 19, 2010Date of Patent: February 21, 2012Assignees: SBI Biotech Co., Ltd., Crystalgenomics, Inc.Inventors: Takayuki Irie, Masaaki Sawa, Sayuri Ito, Chika Tanaka, Seong Gu Ro, Choul Hong Park
-
Patent number: 8053435Abstract: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.Type: GrantFiled: November 1, 2007Date of Patent: November 8, 2011Assignees: Korea Research Institute of Chemical Technology, Crystalgenomics, Inc.Inventors: Cheol Hae Lee, Hee Jung Jung, Jae Hak Kim, Won Jang Jeong, Joong Myung Cho, Seong Gu Ro, Young Lan Hyun, Cheol Soon Lee, Dongkyu Shin
-
Publication number: 20110190299Abstract: An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.Type: ApplicationFiled: April 19, 2010Publication date: August 4, 2011Applicants: SBI BIOTECH CO., LTD., CRYSTALGENOMICS, INC.Inventors: Takayuki Irie, Masaaki Sawa, Sayuri Ito, Chika Tanaka, Seong Gu Ro, Choul Hong Park
-
Patent number: 7973060Abstract: A compound which is effective for inhibiting Fab I, and a method for treating a bacterial infection.Type: GrantFiled: October 11, 2006Date of Patent: July 5, 2011Assignee: CrystalGenomics, Inc.Inventors: Cheol Min Kim, Dong Gyu Shin, Seonggu Ro, Joong Myung Cho, Young Lan Hyun
-
Publication number: 20110028507Abstract: Disclosed herein are pyridine derivatives, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIF ? in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF-related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.Type: ApplicationFiled: August 8, 2008Publication date: February 3, 2011Applicant: CRYSTALGENOMICS, INC.Inventors: Sun Nam Kim, Yong Rae Hong, Dongkyu Shin, Seonggu Ro, Joong Myung Cho, Mi Jung Lee, Ho Jin Chang
-
Publication number: 20100069630Abstract: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.Type: ApplicationFiled: November 1, 2007Publication date: March 18, 2010Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CRYSTALGENOMICS, INCInventors: Cheol Hae Lee, Hee Jung Jung, Jae Hak Kim, Won Jang Jeong, Joong Myung Cho, Seong Gu Ro, Young Lan Hyun, Cheol Soon Lee
-
Patent number: 7179832Abstract: Novel compounds having hydroxybenzoimidazole carboxylic amide are useful for inhibiting glycogen synthase kinase 3?(GSK-3?).Type: GrantFiled: January 20, 2004Date of Patent: February 20, 2007Assignees: Crystalgenomics, Inc., Yuyu Inc.Inventors: Joong Myung Cho, Seonggu Ro, Tae Gyu Lee, Kyung Joo Lee, Dongkyu Shin, Young-Lan Hyun, Seung Chul Lee, Jin Hwan Kim, Young Ho Jeon